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Abstract: Tanshinone I (Tan-I) is a diterpene quinone extracted from the traditional herbal 
medicine Salvia miltiorrhiza Bunge. Recently, Tan-I has been reported to have anti-tumor 
effects. In this study, we investigated the growth inhibition and apoptosis inducing 
effects of Tan-I on three kinds of monocytic leukemia cells (U937, THP-1 and SHI 1). 
Cell viability was measured by MTT assay. Cell apoptosis was assessed by flow cytometry 
(FCM) and AnnexinV/PI staining. Reverse transcriptase polymerase chain reaction 
(RT-PCR) and PCR–enzyme-linked immunosorbent assay (ELISA) were used to detect 




human telomerase reverse transcriptase (hTERT) expression and telomerase activity before 
and after apoptosis. The activity of caspase-3 was determined by Caspase colorimetric 
assay kit and Western blot analysis. Expression of the anti-apoptotic gene Survivin was 
assayed by Western blot and Real-time RT-PCR using the ABI PRISM 7500 Sequence 
Detection System. The results revealed that Tan-I could inhibit the growth of these three 
kinds of leukemia cells and cause apoptosis in a time- and dose-dependent manner. After 
treatment by Tan-I for 48 h, Western blotting showed cleavage of the caspase-3 zymogen 
protein with the appearance of its 17-kD subunit, and a 89-kD cleavage product of poly 
(ADP-ribose) polymerase (PARP), a known substrate of caspase-3, was also found clearly. 
The expression of hTERT mRNA as well as activity of telomerase were decreased 
concurrently in a dose-dependent manner. Moreover, Real-time RT-PCR and Western blot 
revealed a significant down-regulation of Survivin. We therefore conclude that the 
induction of apoptosis by Tan-I in monocytic leukemia U937 THP-1 and SHI 1 cells is 
highly correlated with activation of caspase-3 and decreasing of hTERT mRNA expression 
and telomerase activity as well as down-regulation of Survivin expression. To our 
knowledge, this is the first report about the effects of Tan-I on monocytic leukemia cells. 
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1. Introduction 
The use of herbal medicines has become widely accepted as a realistic option for the treatment of 
malignant disease in recent years [1]. Danshen (Salvia miltiorrhiza Bunge) is one of the widely used 
Chinese herbal medicines in clinical practice that has been proved to have antimicrobial and 
antioxidant properties [2,3]. Tanshinone I (Tan-I), as shown in Figure 1, is a diterpene quinine derived 
from Danshen [4]. Recently, Tan-I has been proved to have anticancer effects in a large variety of 
cancers such as colon [5], lung [6] and breast cancer [7]. 
Though Tan-I has been proved to be very effective in treating a variety of malignancies, many of its 
anti-tumor mechanisms have not been elucidated. Currently, there is no detailed laboratory evidence 
showing the mechanisms of Tan-I on myeloid leukemia cells. In order to clarify some of its 
anti-leukemia mechanisms, we investigated the apoptotic effects of various concentrations of Tan-I 
(10-50 μmol/L) on three kinds of monocytic leukemia cells, U937, THP-1 and SHI 1, in vitro.  
2. Experimental 
2.1. Main Reagents 
Tan-I was kindly provided by Prof. Pei-Qing Liu. The concentration of stock solution is 50 mM 
with DMSO (Dimethyl sulfoxide, Sigma) and it was diluted to working concentration immediately 
before use. Reverse transcriptional kit, TRIZOL, Telomerase and Caspase-3 colorimetric assay kits 
were purchased from R&D systems (Minneapolis, MN, US). Antibodies against Caspase-3, Survivin 




(Germany). PCR primers used in this study were synthesized by Life Technologies Corporation 
(Shanghai, China). All other reagents were obtained from Sigma-Aldrich Inc. (St. Louis, MO, USA). 
Figure 1. The molecular structure of Tan-I. Reprinted with permission from Chinese 
Science Press [4]. 
 
2.2. Cell Culture   
U937, THP-1 and SHI 1 cells were provided by the central laboratory of Sun Yat-sen university 
cancer center. Normal peripheral blood monocytes (NPBMs) were isolated from healthy volunteers 
after obtaining informed consent, by means of Ficoll density gradient centrifugation (specific gravity, 
1.077; Shanghai Reagent Factory, Shanghai, China). Cells were cultured in RPMI-1640 medium 
supplemented with 10% fetal calf serum (FBS), 100U/mL penicillin and l00 µg/mL streptomycin, in a 
humidified incubator with 5% CO2 at 37 °C. All cells were passaged twice weekly and routinely 
examined for mycoplasma contamination. Cells in logarithmic growth phase were used for   
further experiments. 
2.3. Cell Growth Inhibitory Rate (MTT Assay) 
Cell inhibitory rate was assayed using the microculture tetrazolium method. Briefly, U937, THP-1 
and SHI 1 cells and NPBMs in logarithmic growth phase were collected, and 2 × 10
5 cells/well were 
dispensed within 96-well culture plates in 100-mL volumes. Then different concentrations of Tan-I (10, 
20, 30, 40 and 50 μmol/L) were put in different wells. Every one of the concentrations above was 
regarded as one observed group while there was no drug in the control group. Each of the observed 
groups or control group contained six parallel wells. Culture plates were then incubated for 24, 48, and 
72 h, prior to the addition of tetrazolium reagent. MTT working solution was prepared as follows: 5 mg 
MTT/mL phosphate-buffered saline (PBS) was sterilized by filtering with 0.45-μm filters. To each of the 
above cultured wells, 20 μL of MTT working solution was added and then incubated continuously for 4 h. 
All culture medium supernatant was removed from the wells after each of the plates was centrifuged  
(1000 rpm, 15 min) and replaced with 100 μL of DMSO. Following thorough solubilization, the 




inhibitory rate was calculated according to the following formula: Cell growth inhibitory rate = [(A value of 
control group – A value of observed group)/(A value of controlled group)] × 100%. 
2.4. Real-Time RT-PCR Detection of Survivin 
After treatment by different concentrations of Tan-I for 48 h, cells were harvested and the total 
RNA was extracted by using TRIZOL reagent according to the instructions described on the kit. Then 
the expression of Survivin was detected by Real-time RT-PCR using the ABI PRISM® 7500 Sequence 
Detection System (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions. 
The survivin primers were 5’-AAAGAGCCAAGAACAAAATTGC-3’ (sense) and 
5’-GAGAGAGAAGCAGCCACTGTTAC-3’ (antisense), generating a 138 base pair product. For 
RT-PCR reaction, 250 ng of total RNA were subjected to cDNA synthesis and subsequently amplified 
during 30 PCR cycles (0.5 sec at 95 °C; 10 sec at 60 °C; 10 sec at 72 °C). Detection limits of the PCR 
assays were 10
4 copies for survivin. The threshold cycle (Ct) was calculated by the instrument's 
software (7500 Fast System). 
2.5. Telomerase Activity and hTERT Assay   
After the cells were treated by different concentrations of Tan-I for 24, 48, and 72 h, telomerase 
activity was measured quantitatively by the TRAP–enzyme-linked immunosorbent assay (ELISA) 
based on the modified telomere repeat amplification protocol (TRAP). The sequences of the primers 
were: CX 5’-CCCTTACCCTTACCCTTACCCTTA-3’ and TS 5’-AATCCGTCGAGCAGAGTT-3’. 
Cell extracts were prepared according to TRAP. Telomerase added telomeric repeats TTGGG to the 
3 -end of the biotin-labeled synthetic P1-TS primer. Then these elongation products were amplified by 
PCR using the primers P1-TS and P2-CX to generate PCR products with the telomerase-specific 
6-nucleotide increments. Next, an aliquot of the PCR product was denatured and hybridized to a 
dioxigenin-DIG-labeled, telomeric repeat-specific detection probe. The final product was immobilized 
to a streptavidin-coated microtiter plate via the biotin-labeled primer and detected with an antibody 
against dioxigenin (anti-DIG POD) that was conjugated to peroxidase. The probe was visualized by 
virtue of peroxidase metabolizing TMB to form a colored reaction product. Finally, the absorbance of 
the samples was measured at 450 nm (with a reference wavelength of approximately 690 nm) using a 
microtiter plate (ELISA) reader within 30 min after addition of the stop reagent. Absorbance values 
were reported as the A450 nm–A690 nm.  
RT-PCR was also used to detect hTERT expression. Total RNA was extracted from 1 × 10
6 cells 
(after exposure to various concentrations of Tan-I for 48 h) with Trizol RNA kit (Life Technologies, 
Gaithersburg, Md., USA). To generate hTERT cDNA, a 20-μL reaction containing 1μg of total RNA, 
25 mmol/L MgCl2, 10 × PCR buffer, 10 mmol/LDntp, 0.1 MDTT, 1 unit/μL of RNase inhibitor,  
200 units of murine leukemia virus reverse transcriptase (Life Technologies, Gaithersburg, Md., USA), 
and 2.5 μmol/L of random hexamers was incubated for 10 min at 65 °C. The samples were then 
incubated for 60 min at 37 °C, 5 min at 80 °C, and then 5 min at 4 °C. Then 2 μL of reverse 
transcription product was amplified using the primers yielding a 235-bp fragment. The conditions for 
PCR were: 94 °C for 2 min, 94 °C for 45 s, 54 °C for 30 s, 72 °C for 60 s, 35 cycles, and 72 °C for  




samples (extracted samples were heated at 70 °C for 10 min). PCR products were assayed by 1.5% 
agarose gel electrophoresis. 
2.6. Caspase-3 Activity Assay 
The activity of caspase-3 was determined by Caspase colorimetric assay kit according to the 
manufacturer’s protocol. Briefly, 1 × 10
6 cells treated with different concentrations of Tan-I for 24, 48 
or 72 h, were collected, washed with ice-cold PBS and lysed in a lysis buffer. The cell lysates were 
tested for protease activity using a caspase-specific peptide conjugated with the color reporter 
molecule p-nitroanaline. The chromophore p-nitroanaline, cleaved by caspases, was quantitated with a 
spectrophotometer at a wavelength of 405 nm. The caspase enzymatic activities in cell lysates were 
directly proportional to the color reaction.   
2.7. Western Blotting Analysis of Caspase-3 and Survivin 
After the cells were treated with different concentrations of Tan-I for 48 h, Survivin and caspase-3 
was detected by Western blotting. 1 × 10
6 cells were washed with ice-cold PBS twice and lysed with 
cell lysis buffer at 4 °C for 30 min. Cell debris was removed by centrifugation at 15,000 × g for 15 min 
at 4 °C. Equal amounts of proteins were separated by 10% SDS-PAGE and transferred onto 
nitrocellulose membrane. The membranes were first stained to confirm the uniform transfer of all 
samples and then incubated in the blocking solution for 2 h at room temperature. The membranes were 
first incubated with monoclonal antibodies at a dilution of 1:1000 for 2 h, followed by extensive 
washing with PBS twice and TBST twice. The membranes were then incubated with corresponding 
horseradish peroxidase-conjugated secondary antibodies (1:1000 dilution) and washed with TBST. 
β-actin was used as an internal control. The immunoreactive proteins were detected using an ECL 
Western blotting detection system. 
2.8. Flow Cytometry (FCM) Detection 
After the cells were treated with different concentrations of Tan-I for 48 h, 1 × 10
6 cells were 
collected, stained with annexin V and propidium iodide (PI), and then subjected to flow cytometry 
analysis using FACScan (Becton Dickinson; Mountain View, CA).   
2.9. Statistical Analysis 
All experiments were performed in triplicate. The results were expressed as mean ± SD. For 
statistical analysis, Student’s t-test were performed using SAS 6.12 software. Statistical significance 
was accepted at the level of P < 0.05. 
3. Results 
3.1. Tan-I Inhibits Monocytic Leukemia Cell Growth 
To investigate the growth inhibition effects of Tan-I on leukemia U937, THP-1 and SHI 1 cells, as 




concentrations of Tan-I for 24, 48 and 72 h. As shown in Figure 2, Tan-I (over 20 μmol/L) had 
significant growth inhibition effects on U937, THP-1 and SHI 1 cells in a dose-and time-dependent 
manner, while there was no significant cytotoxicity of Tan-I on NPBMs compared to the target 
leukemia cells. Tan-I with concentrations of 40–50 μmol/L showed much higher growth inhibitory 
effect than with lower concentrations (p < 0.01). 
Figure 2. Monocytic leukemia U937, THP-1 and SHI 1 cell growth inhibitory rate caused 
by Tan-I.   
 
 
U937, THP-1 and SHI 1 cells were treated with different concentrations of Tan-I for 24, 48 and  
72 h. The cell growth inhibitory rate was determined by MTT assay, as described in ”Methods”. Tan-I 
(over 20 μmol/L) was able to inhibit cell growth in both dose- and time-dependent manner. The cell 
growth inhibitory rate of Tan-I between 40 μmol/L and 50 μmol/L was much higher than that of  
10 μmol/L concentration of Tan-I (*: p < 0.01), and there was no significant difference of cell growth 
inhibitory rate between U937, THP-1 and SHI 1 cells after treatment by 10 or 20 μmol/L Tan-I 
( p  0.05). 
3.2. Tan-I Inhibits Survivin Expression 
After treatment by different concentrations of Tan-I for 48 h, Survivin expression was first detected 
by Real-time RT-PCR. As shown in Figure 3A, the expression (copies/mL) of survivin gradually 
decreased in a dose-dependent manner after Tan-I treatment.   
To confirm whether down-regulation of Survivin protein was also involved in Tan-I treated cells, 
Western blot analysis was also used to detect the expression of Survivin protein. As shown in Figure 
3B, Survivin expression was down-regulated dramatically in a dose-dependent manner after Tan-I 




Figure 3. Expression of Survivin in monocytic leukemia U937 cells (top panels), THP-1 
cells (middle panels) and SHI 1 cells (bottom panels). (A) Survivin expression was 
detected by Real-time RT-PCR using the ABI PRISM® 7500 Sequence Detection System 
after total RNA was extracted. (B) Survivin expression was detected by Western blot 
analysis. Expression of Survivin was down-regulated in U937, TPH-1 and SHI 1 cells, 
especially after treatment by 40 or 50 μmol/L Tan-I for 48 h, expression of Survivin was 
undetectable in SHI 1 cells. -actin was used as control. 
 
3.3. Tan-I Inhibits Telomerase Activity and hTERT mRNA Expression 
Telomerase activity was detected in U937, THP-1 and SHI 1 cells.  As shown in Figure 4A, 
telomerase activity of Tan-I treated cells decreased remarkably after Tan-I treatment: the higher the 
Tan-I concentration, the lower the telomerase activity in the leukemia cells, especially at 72 h—the 
telomerase activity was undetectable by this method. 




Figure 4. Telomerase activity and hTERT mRNA expression in U937 (top panel), THP-1 
(middle) and SHI 1 (bottom panel) cells. (A) Telomerase activity. Telomerase activity 
decreased in both a time- and dose-dependent manner after Tan-I treatment, and telomerase 
activity at 40 and 50 µmol/L Tan-I treated cells was down-regulated remarkably compared 
to that of lower concentrations of Tan-I treated cells and that of the controlled groups 
(p0.01). (B) hTERT mRNA expression of Tan-I treated cells after treatment by different 
concentrations of Tan-I for 48 h. M: marker: DL 2000. P: positive control, N: negative control. 
lanes 1–5 were 10, 20, 30, 40 and 50 µmol/L Tan-I. 
 
 
hTERT cDNA was also detected by RT-PCR.  The full length of hTERT cDNA was 4015 bp, 
encoding a peptide with 1132 amino acids. The PCR product of should be 235 bp. The agarose gel 
electrophoresis result showed that the length of the PCR product was consistent with expectations. As 
shown in Figure 4B, hTERT mRNA expression decreased gradually along with increasing 
concentrations of Tan-I. No hTERT mRNA expression product was detected when exposed to 40 and 




3.4. Tan-I Activates Caspase-3 
In order to understand the activation of the caspase cascade during Tan-I induced apoptosis in 
leukemia cells, we first investigated caspase-3 activity after the cells were treated with different 
concentrations of Tan-I for 24, 48 or 72 h. As shown in Figure 5A, the colorimetric assay revealed that 
caspase-3 activity increased remarkably in a time-dependent manner. 
Figure 5. Caspase-3 activity detected by colorimetric assay and Western blot in U937 (top 
panel), THP-1 (middle) and SHI 1 (bottom panel) cells. (A) Colorimetric assay of 
caspase-3 activity. Caspase-3 activity was measured as described in the methods. 
Caspase-3 activity increased remarkably in both a time- and dose-dependent manner;  
(B) Western blot of caspase-3. Caspase-3 was activated by the loss of the caspase-3 
proenzyme (32-kD) and the appearance of its 17-kD subunit (Caspase-3 panels) after the 
cells were exposed to different concentrations of Tan-I for 48 h. Tan-I treatment also 
caused a dose-dependent cleavage of PARP, with the appearance of an 89-kD fragment 
and disappearance of the intact 116-kDa PARP (PARP panels). Bottom panel: Actin 
control. For all panels, Lane 1, 2, 3, 4 and 5 were 10, 20, 30, 40 and 50 μmol/L Tan-I. 




To estimate the contribution of caspase-3 to Tan-I-induced cell apoptosis, the proteolytic cleavage 
of pro-caspase-3 was also detected by Western blotting analysis. As shown in Figuge 5B, treatment of 
the cells with different concentrations of Tan-I for 48 h resulted in the cleavage of the 32-kD caspase-3 
zymogen protein and the appearance of its 17-kD subunit. To confirm that Tan-I induced the activation 
of caspase-3, the cleavage of poly (ADP-ribose) polymerase (PARP) was also examined by Western 
blotting. As shown in Fig. 5B, Tan-I treatment caused the time-dependent proteolytic cleavage of 
PARP, with the appearance of an 89-kD fragment and disappearance of the intact 116-kD PARP. 
3.5. Tan-I Promotes Apoptosis in Leukemia Cells   
After the cells were treated with different concentrations of Tan-I for 48 h, cell apoptosis was 
detected as described in the Methods. Cells were stained with PI and annexin V and then analyzed by 
FCM. The percentage of apoptotic cells increased in a dose-dependent manner. The experiments were 
repeated three times and the results are presented as mean ± SD. 
To show the apoptosis inducing effects by Tan-I in monocytic leukemia U937 TPH-1 and SHI 1 
cells, 1 × 10
6 cells were harvested after treatment by different concentrations of Tan-I for 48 h, then 
stained by PI and annexin V and analyzed by FCM. As shown in Figure 6, Tan-I induced apoptosis on 
leukemia cells in dose-dependent manner. After treatment for 48 h, the apoptotic cells induced by Tan-I 
treatment were 3.2% (Control), 3.8% (10 μmol/L), 15.4% (20 μmol/L), 17.4% (30 μmol/L), 37.8% (40 
μmol/L), 49.7% (50 μmol/L) in U937 cells ( Figure 6A), and 3.5% (Control), 4.2% (10 μmol/L), 
16.9% (20 μmol/L), 21.4% (30 μmol/L), 42.3% (40 μmol/L), 51.2% (50 μmol/L) in TPH-1 cells 
(Figure 6B), and 2.5% (Control ), 4.3% (10 μmol/L), 17.2% (20 μmol/L), 23.3% (30 μmol/L), 46.8% 
(40 μmol/L), 54.2% (50 μmol/L) in SHI 1 cells (Figure 6C), respectively. 
Figure 6. Tan-I induced apoptosis in monocytic leukemia cells. (A) Tan Ι induced 
apoptosis in U937 cells; (B) Tan Ι induced apoptosis in THP-1 cells; (C) Tan Ι induced 
apoptosis in SHI 1 cells. 
(A) 










There are many compounds extracted from Salvia miltiorrhiza Bunge. Tan-I is one of its most 
effective derivatives, which has recently been proved to have activity against a number of cancer  
cells [5–7]. In this study, we found that Tan-I could inhibit cell growth and induce apoptosis on 
monocytic leukemia U937, THP-1 and SHI 1 cells remarkably when the concentration of Tan-I was 
over 20 μmol/L. Caspase-3 activity was upregulated, and Western blot showed cleavage of the 
caspase-3 zymogen protein (32-kD) with the appearance of its 17-kD subunit when apoptosis occurred. 
Tan-I treatment also caused a dose-dependent cleavage of PARP, with the appearance of an 89-kD 
fragment and loss of the intact 116-kD PARP. The hTERT mRNA expression detected by RT-PCR was 
down-regulated, and telomerase activity gradually decreased along with increasing concentration of 
Tan-I, especially when the cells were treated with 40 and 50 μmol/L Tan-I for 72 hours. Under these 
conditions, telomerase activity was undetectable by this method. Furthermore, real-time RT-PCR and 




therefore conclude that the induction of apoptosis by Tan-I in monocytic leukemia cells is highly 
correlated with activation of caspase-3 and decreasing hTERT mRNA expression and telomerase 
activity, as well as down-regulation of survivin. These results suggest that Tan-I may be an effective 
agent for the treatment of leukemia. To our knowledge, this is the first report about the roles of Tan-I 
on monocytic leukemia cells.   
Apoptosis plays an important role in the prevention of the development of cancer. The activation of 
apoptosis pathways is a key mechanism by which cytotoxic drugs kill tumor cells [8]. Induction of 
apoptosis has now been considered as an important method for the assessment of the clinical 
effectiveness of many anti-tumor drugs [9, 10]. Survivin is one of the most important cancer specific 
proteins. A lot of studies have demonstrated that survivin may play a number of cell functions 
including inhibition of cell apoptosis, enhancement of tumor cell proliferation by promotion of 
angiogenesis, and cell-cycle regulation, especially at the mitotic process stage [11]. Recent studies 
have shown that survivin overexpression is invariably up regulated in a large number of human 
cancers. Expression of high levels of survivin is closely associated with drug resistance to cancer 
chemotherapy or radiation therapy, and is linked to poor prognosis in cancer patients [11]. In recent 
years, the selective induction of apoptosis via down-regulation of survivin expression in tumor cells 
has been increasingly recognized as a promising approach for cancer therapy [11,12]. Previous studies 
have demonstrated that survivin is essential for cell cycle progression in leukemia cells, and 
down-regulation of survivin expression may lead to programmed cell death, suggesting survivin is an 
appealing new target for the clinical treatment of leukemia [13].
  
Telomerase is a reverse transcriptase that adds nucleotide repeats to telomeres by using a RNA 
template, providing karyotype stability and compensating for the loss of DNA [14,15]. Numerous 
studies have shown that telomerase activity may be detected in over 80% of human tumor cells, and 
telomerase activity is detectable in almost all cancer cell lines [16,17]. In malignant hematological 
diseases, high telomerase activity almost always correlates with disease severity, and the activity of 
telomerase is a very useful index for the diagnosis and clinical staging in hematologic   
malignancies [18,19]. Recent studies [20] suggest that telomerase inhibitors can promote apoptosis in 
many hematologic malignancies such as myeloma, and inhibition of telomerase results in telomere 
shortening, repressed proliferation and altered cell cycle that results in apoptosis in cancer cells [21]. 
This indicates that anti-telomerase therapy can not only enhance apoptosis in tumor cells, but may also 
be one of the most important and effective markers for the selection of new anti-tumor drugs [22, 23]. 
In this study, our results agree with these findings, indicating that down-regulation of telomerase 
activity may be one of the important mechanisms in Tan I-induced cell growth inhibition and apoptosis 
in monocytic leukemia cells. 
5. Conclusion 
Tan-I demonstrates apoptosis-inducing effects on monocytic leukemia cells in vitro by activation of 
caspase-3 and decreasing telomerase activity as well as down-regulation of survivin. These results 
indicate that Tan-I may be an effective anti-leukemia reagents, and that in vivo anti-leukemia effects as 
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